Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450387 | 1.00 | EPHX1 (0.44) | EPHX1TRPM8TRPA1CYP19A1P2RX4 | |
| SCHEMBL4593967 | 0.93 | EPHX1 (0.41) | EPHX1TRPM8TRPA1CYP19A1P2RX4 | |
| SCHEMBL8375724 | 0.85 | EPHX1 (0.42) | EPHX1TRPM8TRPA1CYP19A1P2RX4 | |
| SCHEMBL113449 | 0.84 | TRPM8 (0.48) | EPHX1TRPM8TRPA1CYP19A1ALDH1A1 | |
| SCHEMBL9951572 | 0.80 | EPHX1 (0.51) | EPHX1TRPM8TRPA1CYP19A1TRPV1 | |
| SCHEMBL457824 | 0.80 | EPHX1 (0.51) | EPHX1TRPM8TRPA1CYP19A1TRPV1 | |
| SCHEMBL4455481 | 0.79 | EPHX1 (0.44) | EPHX1TRPM8TRPA1CYP19A1ALDH1A1 | |
| SCHEMBL114683 | 0.78 | EPHX1 (0.46) | EPHX1TRPM8TRPA1CYP19A1ALDH1A1 | |
| Formaldehyde SCHEMBL31298519 | 0.78 | EPHX1 (0.49) | EPHX1TRPM8TRPA1CYP19A1TRPV1 | |
| Acetic Acid SCHEMBL30541669 | 0.78 | EPHX1 (0.49) | EPHX1TRPM8TRPA1CYP19A1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773445-B1 | RETINOL REPLACEMENT IN SKIN TREATMENT | SYMRISE AG (DE) | 2024-07-24 | — | — | EP | claimed |
| CN-111918637-A | Retinol substitute in skin treatment | 西姆莱斯有限公司 | 2020-11-10 | — | — | CN | claimed |
| EP-2785309-B1 | COSMETIC AEROSOL SPRAY WITH LASTING FRESHNESS EFFECT | HENKEL AG & CO KGAA (DE) | 2017-07-12 | — | — | EP | claimed |
| EP-1959915-B1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE AG (DE) | 2015-05-13 | — | — | EP | claimed |
| US-20140271518-A1 | COSMETIC AEROSOL SPRAY WITH LASTING FRESHNESS EFFECT | HENKEL AG & CO. KGAA (DE) | 2014-09-18 | — | — | US | claimed |
| EP-2276356-B1 | WARMING SENSATE COMPOSITION | FIRMENICH & CIE (CH) | 2013-06-19 | — | — | EP | claimed |
| EP-1541039-B1 | Flavour composition comprising cubebol and a further refreshing agent | FIRMENICH & CIE (CH) | 2008-01-02 | — | — | EP | claimed |
| CN-118369431-A | Aptamer for personal healthcare applications | 宝洁公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118355123-A | Aptamer for personal healthcare applications | 宝洁公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118355122-A | Aptamer for personal healthcare applications | 宝洁公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118339295-A | Aptamer for personal healthcare applications | 宝洁公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-116806825-A | Antimicrobial mixture | 西姆莱斯股份公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-115996729-A | Aptamer for personal healthcare applications | 宝洁公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-109475490-B | Hair care composition containing wheat bran extract | 西姆莱斯股份公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-112512541-A | Lactobacillus for skin care | 西姆莱斯有限公司 | 2021-03-16 | — | — | CN | disclosed |
| CN-111918637-A | Retinol substitute in skin treatment | 西姆莱斯有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-20140271518-A1 | COSMETIC AEROSOL SPRAY WITH LASTING FRESHNESS EFFECT | HENKEL AG & CO. KGAA (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20070010574-A1 | Use of a trpm8-activating substance for the treatment of tumours | PLATH THOMAS | 2007-01-11 | — | — | US | disclosed |
| EP-1575673-A2 | USE OF A TRPM8-ACTIVATING SUBSTANCE FOR THE TREATMENT OF TUMOURS | metaGen Pharmaceuticals GmbH (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004054497-A2 | USE OF A TRPM8-ACTIVATING SUBSTANCE FOR THE TREATMENT OF TUMOURS | METAGEN PHARMACEUTICALS GMBH (DE) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271518-A1 | COSMETIC AEROSOL SPRAY WITH LASTING FRESHNESS EFFECT | ALOX5, CUTA, OR51E2 | EPHX1 963/4885TRPM8 308/4885TRPA1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.